Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) Current Deferred Revenue: €0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:JIL Jilin Province Huinan Changlong Bio-pharmacy Co Ltd FRA:JIL
43 GF Score
Price €0.24
GF Value €0.18
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Jilin Province Huinan Changlong Bio-pharmacy Co Current Deferred Revenue?

Jilin Province Huinan Changlong Bio-pharmacy Co FRA:JIL -0.83% 43 Current Deferred Revenue is €0.0 Mil as of Dec. 2025. GuruFocus rates FRA:JIL with a GF Score™ of 43/100 and a GF Value™ of €0.18 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Jilin Province Huinan Changlong Bio-pharmacy Co's current deferred revenue for the quarter that ended in Dec. 2025 was €0.0 Mil.

Jilin Province Huinan Changlong Bio-pharmacy Co Current Deferred Revenue Related Terms

Jilin Province Huinan Changlong Bio-pharmacy Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Jilin Province Huinan Changlong Bio-pharmacy Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jilin Province Huinan Changlong Bio-pharmacy Co Current Deferred Revenue Chart

Jilin Province Huinan Changlong Bio-pharmacy Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Jilin Province Huinan Changlong Bio-pharmacy Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:JIL
43GF Score
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd FRA:JIL
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0.0 Mil mean?
Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) has a Current Deferred Revenue of €0.0 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors.
Is Jilin Province Huinan Changlong Bio-pharmacy Co's Current Deferred Revenue too high?
Jilin Province Huinan Changlong Bio-pharmacy Co's current Current Deferred Revenue is €0.0 Mil. Overall, Jilin Province Huinan Changlong Bio-pharmacy Co has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jilin Province Huinan Changlong Bio-pharmacy Co's Current Deferred Revenue compare to ZTS?
Jilin Province Huinan Changlong Bio-pharmacy Co's Current Deferred Revenue of €0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors. Jilin Province Huinan Changlong Bio-pharmacy Co's current Current Deferred Revenue is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jilin Province Huinan Changlong Bio-pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.18, compared to a current price of €0.24 — trading 33.3% above its estimated fair value. The current Current Deferred Revenue is €0.0 Mil. Jilin Province Huinan Changlong Bio-pharmacy Co's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL), the current Current Deferred Revenue is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) Overvalued in 2026?

Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co stock appears to be overvalued. The current stock price of €0.24 is trading 33.3% above its estimated GF Value™ of €0.18. GuruFocus considers Jilin Province Huinan Changlong Bio-pharmacy Co to be Significantly Overvalued.

Key valuation signals for FRA:JIL:

  • Current Deferred Revenue: €0.0 Mil
  • GF Value™: €0.18 vs. price of €0.24 (33.3% above fair value)
  • GF Score™: 43/100 with 1 warning sign

No single metric tells the full story. See the FRA:JIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jilin Province Huinan Changlong Bio-pharmacy Co Business Description

Other Exchanges 08049:Hong Kong
Address 625 & 639 Nathan Road, Room 1101-2, 11th Floor, Office Tower Two, Grand Plaza, Mong kok, Kowloon, Hong Kong, HKG
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong and Qing Tong. The company has only one business segment. It generates revenue from the Sales of Chinese medicines and pharmaceutical products. Geographically, it derives its entire revenue from the PRC.
43GF Score

Get the complete analysis for FRA:JIL

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.18
GF Value